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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a heritable disorder characterized by symptoms of
inattention and/or hyperactivity/impulsivity. Methylphenidate (MPH) has been shown to block the norepinephrine
transporter (NET), and genetic investigations have demonstrated that the norepinephrine transporter gene (SLC6A2)
is associated with ADHD. The aims of this study were to examine the association of the SLC6A2 -3081(A/T) and
G1287A polymorphisms with MPH response in ADHD.
Methods: This study enrolled 112 children and adolescents with ADHD. A response criterion was defined based on
the Clinical Global Impression-Improvement (CGI-I) score, and the ADHD Rating Scale-IV (ARS) score was also
assessed at baseline and 8 weeks after MPH treatment.
Results: We found that the subjects who had the T allele as one of the alleles (A/T or T/T genotypes) at the -3081
(A/T) polymorphism showed a better response to MPH treatment than those with the A/A genotype as measured
by the CGI-I. We also found a trend towards a difference in the change of the total ARS scores and hyperactivity/
impulsivity subscores between subjects with and without the T allele. No significant association was found
between the genotypes of the SLC6A2 G1287A polymorphism and response to ADHD treatment.
Conclusion: Our findings provide evidence for the involvement of the -3081(A/T) polymorphism of SLC6A2 in the
modulation of the effectiveness of MPH treatment in ADHD.
Background
Attention-deficit/hyperactivity disorder (ADHD) is a
heritable neurodevelopmental disorder affecting about
3-7% of children with its symptoms of inattention and/
or hyperactivity/impulsivity [1]. Methylphenidate (MPH)
has been reported to reduce ADHD symptoms in
approximately 70% of children with ADHD [2,3], and
has been used for the treatment of the disorder for
more than 60 years [4]. It has been well recognized that
the mode of action of MPH in ADHD treatment is in
its blockade of not only the dopamine transporter
( D A T )[ 5 ]b u ta l s ot h en o r e p i n e p h r i n et r a n s p o r t e r
(NET) [6]. One recent study examined if MPH
potentially blocked the human and mouse NET, and
indeed reported the sensitivity of the NET to MPH as
being similar to that of the DAT [7]. Andrews and
Lavin [8] demonstrated that the MPH-induced increase
in cortical cell excitability is mediated by activation of
alpha-2-adrenergic receptors, and they suggested the
possibility of the therapeutic actions of stimulants being
associated with preferential activation of noradrenergic
and/or dopaminergic neurotransmission within the pre-
frontal cortex.
In the prefrontal cortex, where DAT density is low
and NET density is higher, it is unlikely that blockade of
the DAT is a significant contributor to elevated DA
levels in this region. It has been postulated that DA is
transported by the NET in the prefrontal cortex, since
DA has a higher affinity fort h eN E Ta sc o m p a r e dw i t h
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NET-selective (amphetamine), or NET-selective (ato-
moxetine) ADHD medications have one pharmacologi-
cal effect in common, which is to elevate extracellular
levels of DA and NE in the prefrontal cortex [10].
The norepinephrine transporter gene (SLC6A2),
located on chromosome 16q12.2, is composed of 14
exons spanning 48 kb, predicting a protein of 617
amino acids. It has been suggested as one of the candi-
date genes associated with ADHD [11]. Recently, Kim et
al. [12] demonstrated a -3081 A to T single nucleotide
polymorphism (rs28386840) in the promoter region of
the SLC6A2 and its association with ADHD. This study
also identified the -3081(A/T) polymorphism as a func-
tional polymorphism that decreases promoter function.
A c c o r d i n gt oas t u d yb yY a n get al. [13], the G1287A
polymorphism (rs5569), at exon 9 of the SLC6A2,w a s
identified to be associated with MPH response during
the treatment of ADHD. Our previous study [14] pro-
vided evidence for the possible involvement of the
SLC6A2 -3081(A/T) polymorphism in the expression of
ADHD symptoms, such as increased variability in
response time performance. However, in our study, the
family-based and case-control association analyses of the
-3081(A/T) and G1287A polymorphisms of the SLC6A2
found no significant association of these two poly-
morphisms with ADHD. Recently, the finding of no sig-
nificant effect for SLC6A2 G1287A SNP was reproduced
by McGough et al. [15].
Pharmacogenetic studies aim to identify genetic varia-
tions associated with drug treatment response or
adverse effects secondary to medication [16,17]. There is
growing interest in the pharmacogenetics of ADHD and,
until recently, most of the investigations had focused on
the potential susceptibility genes for ADHD, mainly the
genes associated with the dopaminergic systems [18].
Neurobiological and pharmacological evidence points to
dysregulation of the central noradrenergic systems as
the underlying pathophysiology of ADHD [19]. The pre-
sumed mechanism of action of atomoxetine, which has
shown clinical efficacy in treating ADHD patients,
involves the selective norepinephrine reuptake inhibitor
functions [20]. More precisely, atomoxetine is known to
be more specific of the NET than the DAT, which stres-
ses the rationale for the importance of further gene stu-
dies targeting the NET. This evidence supports the
importance for a comprehensive assessment of the
SLC6A2 in ADHD. In addition, the SLC6A2 is therefore
also a likely candidate to assess genetic contributions to
variability in ADHD treatment response. To our knowl-
edge, most of the pharmacogenetic studies of SLC6A2 in
ADHD have been conducted on Western populations
[11,13,21], and there have been no studies on the asso-
ciation between the SLC6A2 -3081(A/T) polymorphism
and the response to MPH treatment. The aims of this
s t u d yw e r et oe x a m i n et h ea s s o c i a t i o no ft h eSLC6A2
-3081(A/T) and G1287A polymorphisms with MPH
response in children and adolescents with ADHD.
Methods
Subjects and clinical assessments
The participants of the present study were recruited
from the Department of Child and Adolescent Psychia-
try at Seoul National University Hospital in Korea. The
diagnostic procedures in our unit have been described
elsewhere [14]. In brief, ADHD was diagnosed based on
t h eD S M - I Vc r i t e r i au s i n gt h eK i d d i e - S c h e d u l ef o r
Affective Disorders and Schizophrenia-Present and Life-
time Version (K-SADS-PL) [22,23]. Subjects with (1) a
history of, or a current neurological disease, including
convulsive disorder, or (2) any evidence of a comorbid
psychiatric condition, such as Tourette’s disorder, men-
tal retardation, pervasive developmental disorder, bipolar
disorder, psychosis, language difficulties or learning dis-
abilities, were excluded. Of the DSM-IV subtypes of
ADHD, the combined subtype was the most common in
our subjects (61.6%), followed by the inattentive (25.9%)
and hyperactive-impulsive (5.4%) subtypes. With regard
to comorbidity, oppositional defiant disorder (13.4%)
was the most common, followed by anxiety disorder
(10.7%) and enuresis (4.5%). For clinical evaluation of
ADHD subjects, the ADHD Rating Scale-IV (ARS)
[24,25] and Clinical Global Impression (CGI) [26] were
administered. The ARS scores were checked by parents,
and CGI scores were checked by psychiatrists.
The study was approved by the institutional review
board (IRB) for human subjects at the Seoul National
University Hospital. Parents provided written informed
consent, and the children or adolescents provided verbal
assent regarding participation in this study.
MPH administration and treatment response
All of the ADHD subjects were administered MPH for a
total of 8 weeks. We adjusted the MPH doses at the
2nd and the 4th week. The dosages were increased until
doses were reached that were sufficient to achieve thera-
peutic effect, on the basis of the parents’ reports of
symptom improvement and side effects, and then these
doses were maintained for the remaining of 8 weeks.
Following Cheon et al. [27,28], clinical assessments were
performed by psychiatrists at baseline prior to medica-
tion and after 8 weeks of MPH treatment in order to
assess the improvement of ADHD symptoms. A “good”
response was defined a priori as a CGI-I score of 1 or 2
points after MPH treatment, whereas a “poor” response
was defined as a CGI-I score in the range of 3-7 points;
the dichotomous response criterion was our primary
outcome measurement [28,29]. We established strong
Kim et al. Behavioral and Brain Functions 2010, 6:57
http://www.behavioralandbrainfunctions.com/content/6/1/57
Page 2 of 8inter-rater reliability before the start of medication
(kappa = 0.89). Psychiatrists were blind to patients’
genotypes.
Genotyping
Genomic DNA was extracted from whole blood lym-
phocytes using a G-DEX TM II Genomic DNA Extrac-
tion Kit (Intron, Korea). The detection of a single
nucleotide polymorphism was based upon analysis of
primer extension products generated from previously
amplified genomic DNA, using a chip-based matrix-
assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry platform (Sequenom,
California, USA). The SLC6A2 polymorphisms were
genotyped as previously described [12,13], with slight
modifications. In brief, oligonucleotide primers [5′-ACG
TTG GAT GAG ACC CTA ATT CCT GCA CCC, and
5′-ACG TTG GAT GTT CAG GAC CTG GAA GTC
ATC for the G1287A polymorphism; 5′-ACG TTG
GAT GGT TTT CTT GCC CCT CAA GTG, and
5′-ACG TTG GAT GAG GGA AGG AAA CCA GGA
GAA for the -3081(A/T) polymorphism] were used to
generate polymerase chain reaction (PCR) products. The
PCR was performed in a volume of 5 μl containing 1 ×
PCR buffer (TAKARA, Japan), 2.5 mM MgCl2, 0.2 mM
of each dNTP, 0.1 U HotStar Taq Polymerase (Qiagen,
Germany), 8 pM of each primer, and 4.0 ng of genomic
DNA. The reaction consisted of denaturation at 95°C
for 15 min, followed by 45 cycles at 95°C for 20 sec, 56°
C for 30 sec, and 72°C for 1 min, with a final extension
at 72°C for 3 min. Following the PCR, unincorporated
dNTP was removed by the addition of 0.3 U of shrimp
alkaline phosphatase and incubation for 20 min at 37°C,
followed by 5 min at 85°C for enzyme inactivation. The
total volume of each reaction was 9 μl, including hME
enzyme (Thermo Sequenase, GE Healthcare, UK), ACT
termination mix, and 5 uM of extension primer. The
primer extension protocol was started at 94°C for 2 min,
followed by 55 cycles at 94°C for 5 sec, 52°C for 5 sec,
and 72°C for 5 sec. After desalting of the reaction pro-
ducts with SpectroCLEAN (Sequenom), samples were
analyzed in the fully automated mode with the MALDI-
TOF MassARRAY system (Bruker-Sequenom, California,
USA). We used blank and negative control for each gen-
otyping plate. For quality control of genotyping data,
duplicate testing of 10% (11 samples) of randomly
selected samples was performed in a blind manner. No
discrepancies were found.
Statistical analysis
Allele frequencies were estimated by counting, and the
Hardy-Weinberg equilibrium was calculated based on
these allele frequencies, using the goodness-of-fit c
2 test.
The estimation of allele frequencies and the test for the
Hardy-Weinberg equilibrium were conducted for the
genotypes of all subjects.
Group differences in the clinical variables involving
continuous data were computed using an independent
two sample t-test or one-way analysis of variance
(ANOVA). Between-group comparisons involving cate-
gorical data were assessed using the c
2 test or Fisher’s
exact test. We used the ANOVA and t-test to assess
correlation between the genotype of SLC6A2 and the
change in the ARS scores in ADHD subjects after MPH
treatment. Predictors of MPH response were tested
using univariate analysis of variance with general linear
model procedure: the dependent variable was the CGI-I
score, and the fixed factors were gene, final MPH dose,
and gene × dose interaction. Effect size estimates for
MPH response were based on Cohen f
2. The signifi-
cance level was set at p = 0.05/2(SNPs)*2(outcome mea-
sures) = 0.01. Power analysis was performed using
G*Power 3 (Heinrich-Heine-University, Dusseldorf,
Germany).
Results
Demographic and clinical characteristics
One hundred and twelve ADHD subjects (mean age =
9.1 ± 2.1 years) were enrolled, consisting of 92 boys
(82.1%) and 20 girls (17.9%) (Table 1). The average total
IQ of the ADHD subjects was 107.4 ± 13.7. The average
score of overall ADHD symptoms according to the ARS,
as measured by the parents of the ADHD subjects, was
26.9 ± 10.3. No baseline differences were found between
the responders and non-responders in their demo-
graphic and clinical characteristics, including the ARS
scores at study entry.
Genetic polymorphisms of SLC6A2
Among the 112 ADHD subjects, the genotype frequen-
cies (A/A homozygous, A/T heterozygous, and T/T
homozygous) of the SLC6A2 -3081(A/T) polymorphism
were 25.9%, 53.6%, and 20.5%, respectively (Table 2).
The genotype frequencies (G/G homozygous, G/A het-
erozygous, and A/A homozygous) of the SLC6A2
G1287A polymorphism were 51.8%, 37.5%, and 10.7%,
respectively. Genotype and allele frequencies observed in
this study were comparable with previously reported
values from the South Korean population [14]. The dis-
tribution of the genotypes for the SLC6A2 -3081(A/T)
polymorphism and SLC6A2 G1287A polymorphism
were in agreement with the expected values of the
Hardy-Weinberg equilibrium (p > 0.05).
Association between the genotypes of SLC6A2 and MPH
response according to the CGI-I assessed by the clinician
There was a trend for association between the geno-
types of the SLC6A2 -3081(A/T) polymorphism and
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the T allele as one of the alleles (A/T or T/T genotypes)
at the -3081(A/T) polymorphism, 61.4% (51 of 83)
showed a good response (CGI-I = 1 or 2) to MPH treat-
ment. However, only 37.9% (11 of 29) of the subjects
with the A/A genotype showed a good response to
MPH treatment (Pearson c
2 (1) = 4.81, p = 0.03) (Table
2). The power to detect differences at the 0.01 level of
significance with our sample size of 112 was 0.35. No
significant association was found between the genotypes
of the SLC6A2 G1287A polymorphism and response to
ADHD treatment.
We found no significant gene effect (F2,80 =0 . 4 9 ,
p = 0.61, f
2 = 0.01) or gene × dose interaction (F13,80 =
1.19, p = 0.30, f
2 =0 . 1 9 )f o rt h eSLC6A2 -3081(A/T)
polymorphism on MPH response.
Table 1 Demographic and clinical characteristics of subjects with ADHD
ADHD
(n = 112)
Responders
(n = 62)
Non-responders
(n = 50)
p-value
Age in yr, mean (SD) 9.1 (2.1) 9.1 (2.0) 9.0 (2.2) 0.79
Sex (M/F) 92/20 54/8 38/12 0.13
IQ, mean (SD) 107.4 (13.7) 107.8 (13.2) 106.9 (14.4) 0.73
ADHD subtypes 0.30
Combined 61.6% 58.1% 66.0%
Inattentive 25.9% 25.8% 26.0%
Hyperactive-impulsive 5.4% 4.8% 6.0%
NOS 7.1% 11.3% 2.0%
Comorbidity
Oppositional defiant disorder 13.4% 8.0% 20.0% 0.07
Anxiety disorder 10.7% 9.7% 12.0% 0.69
Enuresis 4.5% 6.5% 2.0% 0.26
ARS baseline scores, mean (SD)
Total 26.9 (10.3) 25.9 (11.1) 28.3 (8.8) 0.23
Inattentive 15.1 (5.8) 14.2 (5.9) 16.3 (5.6) 0.07
Hyperactivity/impulsivity 11.8 (6.0) 11.6 (6.3) 12.0 (5.7) 0.75
Dosage of MPH (mg/day), mean (SD)
Baseline dose 19.9 (8.3) 18.6 (6.2) 21.5 (10.1) 0.08
Final 2 weeks dose 29.2 (11.6) 28.2 (10.9) 30.4 (12.4) 0.32
ADHD, Attention-Deficit/Hyperactivity Disorder; NOS, Not Otherwise Specified; ARS, ADHD Rating Scale; MPH, Methylphenidate
Table 2 Association between SLC6A2 genotypes and response to MPH treatment according to the CGI-I
Response to MPH by CGI-I
N (% within SLC6A2 genotype)
SLC6A2 genotype Poor
(CGI-I: 3-7)
Good
(CGI-I: 1 or 2)
Total
(% within total number)
p-value
-3081(A/T) polymorphism A/A 18 (62.1%) 11 (37.9%) 29 (25.9%) 0.08
A/T 24 (40.0%) 36 (60.0%) 60 (53.6%)
T/T 8 (34.8%) 15 (65.2%) 23 (20.5%)
A/A 18 (62.1%) 11 (37.9%) 29 (25.9%) 0.03
A/T+T/T 32 (38.6%) 51 (61.4%) 83 (74.1%)
Total 50 (44.6%) 62 (55.4%) 112
G1287A polymorphism G/G 22 (37.9%) 36 (62.1%) 58 (51.8%) 0.12
G/A 24 (57.9%) 18 (42.9%) 42 (37.5%)
A/A 4 (33.3%) 8 (66.7%) 12 (10.7%)
G/G 22 (37.9%) 36 (62.1%) 58 (51.8%) 0.14
G/A+A/A 28 (51.9%) 26 (48.1%) 54 (48.2%)
Total 50 (44.6%) 62 (55.4%) 112
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polymorphism and MPH response according to the ARS
as assessed by the parents
There were no significant differences in the demo-
graphic and clinical characteristics, except the profile of
comorbid enuresis, between the ADHD subjects with
the (A/T + T/T) genotypes and those with the A/A gen-
otype of the -3081(A/T) polymorphism (Table 3).
When we compared the changes in ARS scores after
MPH treatment as the secondary outcome measure-
ment, according to the genotypes of the -3081(A/T)
polymorphism, we found a trend towards a difference in
the change of the total ARS scores [t(1) = 1.92,
p = 0.06] and hyperactivity/impulsivity subscores
[t(1) = 1.73, p = 0.09] between subjects with and with-
out the T allele (Table 4).
Discussion
In this study, we identified a trend for association
between the -3081(A/T) polymorphism of SLC6A2 and
response to MPH treatment in Korean children and
adolescents with ADHD. Those ADHD subjects who
had the T allele as one of the alleles (A/T or T/T geno-
types) at the -3081(A/T) polymorphism showed a better
response to MPH treatment than those with the A/A
genotype, although this relative difference does not pro-
vide definite conclusion on whether the presence of the
T allele is association with a better response or the
absence of the T allele is associated with a poorer
response, given that even the ADHD patients with the T
allele showed only a 61.4% response rate to MPH. In
addition, the ADHD subjects with the T allele showed a
tendency for more symptom reduction after treatment
with MPH than those without the T allele. However, no
significant association was found between response to
MPH and the SLC6A2 G1287A polymorphism. In a pre-
vious study [13], those ADHD subjects who were homo-
zygous for the A allele (A/A genotype) at the G1287A
polymorphism showed less symptom reduction in the
hyperactive-impulsive subscores of the ARS after
Table 3 Demographic and clinical characteristics of ADHD subjects according to genotypes of the -3081(A/T)
polymorphism
ADHD subjects with
A/A genotype
ADHD subjects with A/T
+ T/T genotypes
p-value
Age in yr, mean (SD) 9.0 (2.4) 9.1 (2.0) 0.81
Sex (M/F) 22/7 70/13 0.31
IQ, mean (SD) 107.2 (13.3) 107.5 (14.0) 0.92
ADHD subtypes 0.35
Combined 58.6% 62.7%
Inattentive 34.5% 22.9%
Hyperactive-impulsive 0.0% 7.2%
NOS 6.9% 7.2%
Comorbidity
Oppositional defiant disorder 6.9% 15.7% 0.19
Anxiety disorder 3.4% 13.3% 0.13
Enuresis 13.8% 1.2% 0.02
ARS baseline scores, mean (SD)
Total 23.9 (11.4) 27.9 (9.7) 0.08
Inattentive 13.6 (6.3) 15.6 (5.6) 0.12
Hyperactivity/impulsivity 10.3 (6.9) 12.3 (5.7) 0.14
Dosage of MPH (mg/day), mean (SD)
Baseline dose 19.7 (9.3) 20.0 (8.0) 0.88
Final 2 weeks dose 27.9 (11.1) 29.7 (11.8) 0.48
CGI-I score, mean (SD) 2.8 (0.9) 2.4 (0.8) 0.04
ADHD, Attention-Deficit/Hyperactivity Disorder; NOS, Not Otherwise Specified; ARS, ADHD Rating Scale; MPH, Methylphenidate
Table 4 Comparison reductions in ARS scores after MPH
treatment in ADHD subjects according to genotypes of
the -3081(A/T) polymorphism
Genotype Changes in ARS scores
IA p-value Hy/Imp p-value Total p-value
A/A 5.4 (4.3) 0.54 4.6 (4.1) 0.12 8.4 (7.6) 0.10
A/T 6.2 (4.9) 6.3 (4.5) 12.1 (8.8)
T/T 7.2 (6.6) 7.8 (7.2) 14.7 (12.6)
A/A 5.4 (4.3) 0.38 4.6 (4.1) 0.09 8.4 (7.6) 0.06
A/T + T/T 6.5 (5.4) 6.7 (5.4) 12.8 (10.0)
ARS, ADHD Rating Scale; IA, inattentive subscale; Hy/Imp, hyperactivity/
impulsivity subscale
All values are mean (± S.D.)
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types (G/G or G/A genotypes). The sample size of their
study (35 boys and 10 girls) was smaller than that of
our study (92 boys and 10 girls). The divergent results
between the two studies might reflect methodological
issues, such as sample sizes, ethnic differences, inclusion
and exclusion criteria, or instruments to assess drug
treatment response.
It is important to understand the potential functional
significance of the SLC6A2 -3081(A/T) polymorphism.
Kim et al. [12] reported that the -3081(T) allele signifi-
cantly decreases promoter function compared with the
-3081(A) allele, which was assessed using synthesized
promoter-reporter constructs. The authors also demon-
strated that Slug and Scratch, neural-expressed tran-
scriptional repressors, decrease the promoter activity
only when it contains the -3081(T) allele. In their study,
the frequency of the -3081(T) allele was significantly
higher in the ADHD probands than in the controls, and
the A/T and T/T genotypes were overrepresented in the
ADHD subjects. However, studies of the association
between SLC6A2 -3081(A/T) polymorphism and ADHD
have yielded mixed results, with several studies finding
some evidence for association [12,27], and our previous
paper providing no evidence for association [14].
Recently, Jung et al. [30] reproduced in a Korean popu-
lation that the frequency of the -3081(T) allele was sig-
n i f i c a n t l yh i g h e ri nA D H Ds u b j e c t st h a ni nc o n t r o l s .
Our current data that the ARS total score at baseline
showed a higher trend (p = 0.08) in those with at least
one -3081(T) allele might slightly support the previous
findings from the Korean population. Downregulated
promoter function of SLC6A2 and consequent decrease
in transcriptional activity, as reported by Kim et al. [12],
may result in low levels of NET. Our results, which sug-
gest a good response to MPH in ADHD is associated
with the presence of the -3081(T) allele of SLC6A2,m a y
be explained by reduced levels of NET within the brain.
On the other hand, it is possible that subjects with the
-3081(T) allele have their ADHD in tighter relation with
the action of NET, and therefore pharmacologically
blocking this transporter is associated with relatively
better treatment response. Thus, investigating response
to treatment and its mechanism of action in terms of
molecular and genetic findings might help us to identify
more homogeneous subgroups of ADHD [31]. Further
studies using imaging genetic approaches based on sin-
gle photon emission computerized tomography (SPECT)
or positron emission tomography (PET) will be required
to investigate NE gene effects on regional cerebral per-
fusion or metabolism in ADHD and to evaluate the
association of SLC6A2 genetic variation with levels of
NE activity in the brain.
The search for candidate genes associated with ADHD
has been largely driven by the understanding that medi-
cations for this disorder have drug targets in the cate-
cholamine neurotransmitter systems [32]. Although
knowledge about the presumed mechanisms of action of
ADHD medication, including MPH, initially informed
the research into genetic polymorphisms associated with
the disorder, these same polymorphisms have been and
continue to be logical candidates to predict medication
outcome, in terms of symptom response and side effect
profiles [33]. Recent studies suggest that candidate
genes involved in catecholamine pathways influence
individual responses to ADHD treatments. However, as
mentioned above, the majority of pharmacogenetic stu-
dies of ADHD investigating response or tolerability to
medication have focused mainly on dopaminergic genes
[11]. Polymorphisms in noradrenergic genes, such as
alpha-2A-adrenergic receptor gene (ADRA2A)o r
SLC6A2, may have a specific effect as proposed on
MPH response [13,21,34]. Mick et al. [21] have con-
ducted a genome-wide association study (GWAS) on a
sample of 187 ADHD children and found that 2 SNPs
that tag NET gene (SLC6A2) were suggestively associa-
tion with MPH response. On the other hand, in a study
conducted by Kooij et al.[ 3 5 ] ,t h ep o l y m o r p h i s m si n
the SLC6A2 were not associated with MPH response.
Here, of note is that the study by Ramoz et al.[ 1 1 ]h a s
demonstrated that the SLC6A2 predicted response to
another pharmacological agent for ADHD: atomoxetine.
In these contexts, our findings demonstrate that the
-3081(A/T) polymorphism of SLC6A2 might modulate
the effectiveness of MPH treatment on ADHD. To date,
this study is the first to examine the association of the
SLC6A2 -3081(A/T) polymorphism with MPH response
in ADHD. The result of Ramoz et al. [11] and ours
combined further suggest that the SLC6A2 -3081(A/T)
polymorphism constitute a common pathway for the
treatment effects of both MPH and atomoxetine.
Several limitations to this study should be noted. First,
this was a naturalistic study, and we did not have a pla-
cebo arm in this trial. It is likely that a placebo response
in our study group would have decreased the statistical
power by reducing the measurement precision of MPH
response. However, naturalistic study designs may be
valuable to better appreciate the role of genetic factors in
routine clinical practice beyond the realm of controlled
clinical trials. Second, our study population included all
of the subtypes of ADHD, which might have contributed
to clinical heterogeneity; the subtypes may have acted as
potential confounders of the investigated association.
Third, MPH was administered with no control of adher-
ence by investigators. Fourth, we did not control for the
two types of MPH products: immediate-release (IR)
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not find a significant difference in clinical improvement
between the ADHD subjects treated with IR MPH and
those treated with SR MPH (data not shown, but avail-
able upon request). Lastly, but perhaps most importantly,
two titration visits in our study design were probably
insufficient, which may have resulted in lower mean daily
doses at endpoint, and it might explain the low response
rate observed in our results compared to the reported
average response rate of approximately 75% in controlled
outpatient stimulant trials [36].
Conclusion
In conclusion, our data suggest that the -3081(A/T)
polymorphism of SLC6A2 might be involved in the
modulation of the effectiveness of MPH treatment in
ADHD. Further pharmacogenetic investigations should
expand the focus to include other functional poly-
morphisms of the SLC6A2,g i v e nt h ei n c r e a s e du s eo f
noradrenergic drugs in the treatment of ADHD symp-
toms [37], in order to better understand the role of
genetic variation in a good vs. poor response to drug
treatment for ADHD.
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